Bures-sur-Yvette, France

Françoise Gellibert


 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Françoise Gellibert: Innovator in Medicinal Chemistry

Introduction

Françoise Gellibert is a notable inventor based in Bures-sur-Yvette, France. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on isoquinoline compounds. His research focuses on developing pharmaceutical compositions that can effectively treat various pathologies.

Latest Patents

Françoise Gellibert holds a patent for isoquinoline compounds, which includes a process for their preparation and pharmaceutical compositions containing them. The patent describes a compound of formula (I), wherein the substituents are defined in the description. These medicinal products are particularly useful in treating or preventing conditions resulting from the activation of the RhoA/ROCK pathway and the phosphorylation of the myosin light chain. He has 1 patent to his name.

Career Highlights

Gellibert is associated with Les Laboratoires Servier, a prominent pharmaceutical company. His work there has been instrumental in advancing the understanding and application of isoquinoline compounds in medicine. His research has the potential to impact the treatment of various diseases significantly.

Collaborations

Throughout his career, Françoise Gellibert has collaborated with esteemed colleagues, including Stéfano Chimenti and Christine Courchay. These collaborations have enriched his research and contributed to the development of innovative medicinal products.

Conclusion

Françoise Gellibert is a distinguished inventor whose work in medicinal chemistry has led to valuable advancements in pharmaceutical science. His contributions, particularly in the area of isoquinoline compounds, highlight the importance of innovation in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…